Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-03 · accession 0001610717-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-07 | 2025-01-04 | CHRS | Reider Paul | Chief Commercial Off | F - Tax | $1.66 | -2,277 | 86.9K | -3% | -$3,780 |
| D | 2025-01-07 | 2025-01-03 | CHRS | Reider Paul | Chief Commercial Off | A - Grant | $0.00 | +160.0K | 160.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-04 | F | D | 2,277 | $1.66 | 86,927 | D | — | — | (F1) Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction. |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-01-03 | A | A | 160,000 | $0.00 | 160,000 | D | $1.66 · — to 2035-01-03 | 160,000 Common Stock | (F2) The underlying shares subject to the option vest and become exercisable as to 1/4th of the total number of shares on the one year anniversary of January 3, 2025 and 1/48th of the total number of shares in successive, equal monthly installments thereafter, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. |